CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases

Description

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

Conditions

Liver Metastases

Talk to us

Study Overview

On this page

Study Details

Study overview

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

Risk-Stratified Adjuvant Therapy: CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases

CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases

Condition
Liver Metastases
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed OR being removed at time of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX/FOLFIRI +/- bevacizumab or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023
  • * Must receive ≥ 4 cycles of preoperative chemotherapy
  • * Patients with primary colorectal tumor that will remain in situ
  • * Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori
  • * Unwilling/unable to undergo blood draws for ctDNA, patient or provider-determined
  • * Other active malignancies requiring treatment
  • * Women who are pregnant

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Timothy Newhook, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2026-02-28